SA
CPRX

Strategic Advocates’s Catalyst Pharmaceutical CPRX Stock Holding History

Strategic Advocates’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-181
Closed -$4.21K – 331
2025
Q4 		$4.21K Hold
181
– – ﹤0.01% 445
2025
Q3 		$3.57K Buy
+181
New +$3.72K ﹤0.01% 440
2024
Q3 		– Sell
-14,142
Closed -$219K – 124
2024
Q2 		$219K Buy
14,142
+864
+7% +$13.5K 0.09% 110
2024
Q1 		$212K Buy
+13,278
New +$200K 0.08% 116

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Strategic Advocates's CPRX Position: Q1 2026 in Review

Strategic Advocates sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 181 shares — an estimated $4.21K sold.

Strategic Advocates first reported a position in CPRX in Q1 2024 and held it in 4 quarters. The position peaked at $219K in Q2 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Strategic Advocates reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Strategic Advocates sold 181 Catalyst Pharmaceutical shares in Q1 2026, an estimated $4.21K.
  • Strategic Advocates first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 4 quarters.
  • Strategic Advocates's Catalyst Pharmaceutical position peaked at $219K in Q2 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.